Status and phase
Conditions
Treatments
About
This phase II trial studies how well IBI308 combined with paclitaxel/albumin-bound paclitaxel work in treating participants with small cell lung cancer after failing to platinum-etoposide chemotherapy.
Full description
Primary objective :
To estimate progression free survival (PFS) probability of patient who recurrent SCLC treated with IBI308 combined with paclitaxel/abumin-bound paclitaxel following progression on platinum-etoposide chemotherapy.
Secondary Objectives:
I.To evaluate the objective remission rate (ORR), disease control rate. (DCR),durative time of remission ( DoR)and overall survival (OS) of IBI308 combined with paclitaxel/abumin-bound paclitaxel following progression on platinum-etoposide chemotherapy.
II.To evaluate the safety of IBI308 combined with paclitaxel/abumin-bound paclitaxel following progression on platinum-etoposide chemotherapy.
Exploratory Objectives To evaluate the correlation of biomarkers with efficacy and toxicity.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
30 participants in 1 patient group
Loading...
Central trial contact
Junling Li, doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal